Cell Genesys pact highlights cancer vaccine value

Cell Genesys' $320 million partnership deal with Takeda for its GVAX prostate cancer vaccine thrilled investors, who boosted the South San Francisco biotech's stock by 31 percent after the announcement. The Motley Fool sounds unimpressed by the numbers, but $50 million upfront is a solid standout in the development field. Takeda is also an experienced player in the prostate cancer field, with a successful track record for the hormone therapy Lupron. The cancer vaccine is in two late stage studies, with data due in 2009. In the meantime, analysts have also been pondering the possible implications the Cell Genesys deal could have on a pact covering Dendreon's immunotherapy, Provenge.

- read the report in the Motley Fool

ALSO: Cuba has begun clinical testing of an experimental prostate cancer vaccine. Report

Suggested Articles

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.